药群论坛

 找回密码
 立即注册

只需一步,快速开始

查看: 585|回复: 1
打印 上一主题 下一主题

[市场快讯] 2013年糖尿病药物销售额TOP20

[复制链接]
跳转到指定楼层
楼主
朵朵7 发表于 2014-11-11 18:26:42 | 只看该作者 回帖奖励 |正序浏览 |阅读模式

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区

您需要 登录 才可以下载或查看,没有帐号?立即注册  

x
2013年糖尿病药物销售额TOP20

                               
登录/注册后可看大图
  

                               
登录/注册后可看大图
发布日期:2014-11-11  来源:genengnews  

2013年,糖尿病药物市场拼杀激烈,在残酷的市场竞争中,哪一家公司笑到最后?本文就为大家盘点一下2013年销售额前20名。


                               
登录/注册后可看大图

这份榜单中有一些公司没有出现,因为它们没有公布去年和今年的销售额,如强生公司。该公司的糖尿病药物Invokana(坎格列嗪)销售额并未公之于众,尽管强生单方面宣布该药品的销量很好。但据WellsFargo公司的分析师LawrenceBiegelson估计,2013年Invokana的销售额约为1.22亿美元。

预计明年的榜单中会出现今年新获批的几种药物,比如德国勃林格殷格翰的Jardiance(empagliflozin),这是一类钠-葡萄糖联合转运体2(SGLT2)的抑制剂,用于治疗成人2型糖尿病;还有礼来的Trulicity(dulaglutuide),这是一类胰高血糖素样肽1(GLP-1)受体激动剂,也是用于治疗成人2型糖尿病。

今年1月8号,FDA批准了阿斯利康的SGLT2抑制剂Farxiga(dapagliflozin),而在两个月之前,该药品也获得了欧洲委员会的批准,将以商品名Forxiga上市。Farxiga/Forxiga原来是由阿斯利康和百时美施贵宝两家公司联合研发的,而在今年2月1号,百时美施贵宝以43亿美元的价格将该药品专利卖给了阿斯利康。此外,2014年1月22号,一款名为Xigduo的dapagliflozin和metformin的联合治疗方案获得了欧洲市场委员会批准;XigduoXR也于今年10月29号获得FDA批准,在此之前,该药品也获澳大利亚批准。

诺和诺德的Xultophy与Victoza(liraglutide)联合用药于9月份获得欧洲委员会批准,它出现在了今年的榜单上;Tresiba(insulindegludec)虽然去年未获FDA批准,但于2013年初在欧洲上市。FDA坚持认为Tresiba还应进行新一轮临床试验,与此同时Novo的组合药Ryzodeg(insulindegludec/insulinaspart)可以获批。

                               
登录/注册后可看大图


  • Following is a list of 20 FDA-approved treatments for patients with diabetes ranked by their 2013 sales, as reported by the companies that market them. Drugs are listed by name, sponsor(s), and sales data.

    Missing from the list are several treatments which were either launched last year with no sales numbers furnished by their marketers, or were launched this year. An example of the former is Johnson & Johnson’s Invokana (canagliflozin), which the company said enjoyed “strong sales” last year, without disclosing a figure. The closest to an actual number is a widely quoted estimate by Wells Fargo analyst Lawrence Biegelson projecting that Invokana was to have generated $122 million in first-year 2013 sales.

    Next year’s list could include several diabetes products approved this year. Two examples of these are Boehringer Ingelheim’s Jardiance (empagliflozin), a sodium glucose co-transporter 2 (SGLT2) inhibitor for type 2 diabetes in adults; and Eli Lilly’s Trulicity (dulaglutuide), a weekly glucagon-like peptide-1 (GLP-1) receptor agonist for adults with type 2 diabetes.

    The FDA also approved AstraZeneca’s SGLT2 inhibitor Farxiga (dapagliflozin) on January 8—two months after the European Commission gave its nod to the drug under the trade name Forxiga. Farxiga/Forxiga was developed through AstraZeneca’s former diabetes alliance with Bristol-Myers Squibb, until BMS sold its interest to AZ in a deal completed February 1 and valued at up to $4.3 billion. A twice-daily combination treatment of dapagliflozin and metformin, trade-named Xigduo, won European marketing authorization on January 22, 2014, while a once-daily formulation, Xigduo XR, got FDA’s nod on October 29 and earlier gained Australian approval.

    The EC in September approved Novo Nordisk’s Xultophy, a once-daily single injection combination of Victoza (liraglutide), which appears on this year’s list—and, Tresiba (insulin degludec), which was rejected last year by the FDA but has been marketed in Europe since early 2013. The FDA, however, insisted on another clinical trial assessing Tresiba and a second Novo combo candidate, Ryzodeg (insulin degludec/insulin aspart).


  • #20. Apidra® (insulin glulisine [rDNA origin] injection)

    Company: Sanofi

    2013 sales: $364 million (

回复

使用道具 举报

沙发
feibing 发表于 2014-11-12 19:40:20 | 只看该作者
感谢分享了,辛苦
回复 支持 反对

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册  

本版积分规则

QQ|手机版|药群论坛 ( 蜀ICP备15007902号 )

GMT+8, 2025-7-6 05:22 AM , Processed in 0.105313 second(s), 18 queries .

本论坛拒绝任何人以任何形式在本论坛发表与中华人民共和国法律相抵触的言论! X3.2

© 2011-2014 免责声明:药群网所有内容仅代表发表者个人观点,不代表本论坛立场。

快速回复 返回顶部 返回列表